arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Imunon, Inc.

IMNN
$1.49 ▼ -0.01 (-0.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Imunon, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.2M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -163.9% ↗
FCF / Share $-6.68 ↘
Trailing P/E —
Price / Book 0.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$500.00K
— 0.0% —
Net Income Profit after all expenses
$-14.50M
↑ +22.2% —
FCF / Share Free cash flow per share
$-6.68
↓ -306.9% —
Long-Term Debt Long-term obligations
$5.96M
↑ +18.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality ↑
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters